Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Respiratory Medicine

OA11.06 Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma

Journal of Thoracic Oncology

English

P2.04-21 Real World Experience of Immune Checkpoint Inhibitors in NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK

Journal of Thoracic Oncology

English

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology

English

P3.03-08 Analysis of ESR1 Mutation Spectrum From Non-Small-Cell Lung Cancer in Chinese Patients

Journal of Thoracic Oncology

English

P2.17-14 How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?

Journal of Thoracic Oncology

English

P3.cr-17 an Interesting Case of Long-Term Immunotherapy Response in Metastatic NSCLC

Journal of Thoracic Oncology

English

P2.01-108 Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy

Journal of Thoracic Oncology

English

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases

Journal of Thoracic Oncology

English

MA07.02 Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment

Journal of Thoracic Oncology

English

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Respiratory Medicine

OA11.06 Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma

P2.04-21 Real World Experience of Immune Checkpoint Inhibitors in NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

P3.03-08 Analysis of ESR1 Mutation Spectrum From Non-Small-Cell Lung Cancer in Chinese Patients

P2.17-14 How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?

P3.cr-17 an Interesting Case of Long-Term Immunotherapy Response in Metastatic NSCLC

P2.01-108 Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases

MA07.02 Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer